Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain study targets motivation loss in depressed teens

NCT ID NCT05487885

Knowledge-focused Sponsor: Erika Forbes Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at anhedonia, a symptom of depression where people lose interest or pleasure in activities. Researchers used brain scans, blood tests, and questionnaires to understand this symptom in 123 young people. Some participants also tried treatments like brain stimulation or ketamine to see if they could improve motivation and enjoyment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

123 people

The number who actually took part.

Started

Jul 2022

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

15 to 25 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Phase 1 (all participants) * Current DSM-5 depressive disorder * Severity ≥ 12 on MADRS * Moderate-severe anhedonia (75% of sample) or low anhedonia (25% of sample) Phase 2 (for participants in TBS and ketamine phase, in addition to above) • ≥ 1 failed antidepressant trial (for qualification for Phase 2 of study and definition of non-response to TMS in order to be eligible for ketamine) = Treatment for at least 6 weeks with an antidepressant medication reaching recommended dosage for adults for at least 3 weeks of the treatment (e.g., 20 mg fluoxetine) Exclusion Criteria: Phase 1 (all participants) * Lifetime psychosis, bipolar disorder, or developmental disorder * Serious, unstable neurological disorder (e.g., seizure disorder) * Brain injury with loss of consciousness * Moderate-severe substance use disorder, past 6 mos. * MRI contraindications (e.g., metal in body) Phase 2 (for participants in TBS and ketamine phase, in addition to above) * Serious, unstable respiratory or cardiovascular illness * Pre-TBS: Alcohol binge in past week or \> 3 drinks/day in past 3 days * Pre-ketamine: use of MAOIs in past 2 weeks * Pregnancy * High blood pressure * Current illicit stimulant use * Lifetime recreational ketamine or PCP use

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anhedonia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Anhedonia Depression depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anhedonia Depression

Contacts and locations

Locations

  • Loeffler Building

    Pittsburgh, Pennsylvania, 15213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.